Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo

Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by incorporating the lead candidate into a co-development deal with Daiichi Sankyo.